Colorado hopes to lead next wave of psychedelic movement
Colorado has solidified its position at the forefront of the psychedelic movement with the recent launch of its psilocybin therapy industry. Local leaders are optimistic that this new model will not only serve as a blueprint for other states but also inform the integration of psychedelic modalities into the broader American health care system.
At the Psychedelic Science conference in Denver, Colorado policymakers, including Gov. Jared Polis and Attorney General Phil Weiser, expressed excitement about the potential of these innovative mental health treatments. The event brought together about 8,000 attendees, including celebrities, researchers, and representatives from medical groups such as the American Psychiatric Association and the American Psychological Association.
While drugs like “magic mushrooms” are not yet widely accepted as medicines, they are now available in Colorado. Psychedelic-assisted therapy was legalized by voters in 2022, and the first licensed healing centers began treating patients this month.
Weiser, speaking at the conference, expressed excitement about the potential of natural medicines, particularly in treating conditions such as severe depression, post-traumatic stress disorder, and addiction.
“Colorado voters have once again led an important experiment in public health,” Weiser said. “This is an opportunity for us to research and support individuals in ways that were previously unavailable.”
Polis also commended regulators for establishing a legal framework for businesses and therapists, emphasizing the importance of setting an example for other states in the careful implementation of these therapies.
Both Polis and Weiser highlighted the opportunity for further research into psychedelics as a significant benefit of legalization. Due to federal scheduling of substances like psilocybin, research on their benefits and risks has been limited to small studies and clinical trials.
Dr. Marketa Wills, CEO and medical director of the American Psychiatric Association, emphasized the importance of research and scientific data in integrating psychedelic modalities into modern medicine. She noted that numerous clinical trials using psychedelics to treat various conditions are awaiting consideration by the FDA.
Despite growing evidence of the potential benefits of psychedelics, there remains hesitance within the psychiatric community due to the lack of research into their efficacy and safety profiles. Most medical professionals have not received training on these drugs, leading to a cautious approach in their adoption.
Dr. Andrew Monte, associate director of Rocky Mountain Poison & Drug Safety, conducted a survey on psychedelic tourism, revealing that a significant number of individuals travel to destinations like Colorado to use psychedelics for recreational or medical purposes.
As Colorado’s psychedelic industry continues to grow, businesses like The Psylutions are gearing up to meet the demand for products and services. The emergence of legitimate providers like The Psylutions indicates a shift from underground practices to a regulated industry.
Overall, the integration of psychedelic modalities into modern health care will require further research, education, and careful consideration of their benefits and risks. As Colorado leads the way in this new frontier, it sets an example for other states to follow in exploring the potential of psychedelic therapies.
Subscribe to our newsletter for the latest health news delivered to your inbox.
Original Publication Date:
